Company intelligence / Profile preview

Deafarma

Milan, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

Deafarma was a Milan-based distributor and service provider of Active Pharmaceutical Ingredients (APIs), excipients, and intermediates. The company offered regulatory support, assistance with pharmaceutical dossiers, and technical advice. Deafarma was acquired by Azelis in early 2019; its services and workforce became part of Azelis’s pharma division[1][4].

Modalities: Small molecule
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Deafarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deafarma.

Explore the full profile